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Background: Satellite cell activation is orchestrated by several signals, which induce their differentiation into skeletal
muscle fibers.
Results:Obestatin and the GPR39 receptor exert an autocrine role on the control of myogenesis.
Conclusion: Our data indicate that obestatin/GPR39 is an injury-regulated signal that functions as a myogenic regenerative
system.
Significance: Strategies to enhance obestatin-mediated signaling could be useful in treating trauma-induced muscle injuries
and skeletal muscle myopathies.
The maintenance and repair of skeletal muscle are attributa-
ble to an elaborate interaction between extrinsic and intrinsic
regulatory signals that regulate the myogenic process. In the
present work, we showed that obestatin, a 23-amino acid pep-
tide encoded by the ghrelin gene, and the GPR39 receptor are
expressed in rat skeletal muscle and are up-regulated upon
experimental injury. To define their roles in muscle regenera-
tion, L6E9 cells were used to perform in vitro assays. For the in
vivo assays, skeletal muscle tissue was obtained from male rats
and maintained under continuous subcutaneous infusion of
obestatin. In differentiating L6E9 cells, preproghrelin expres-
sion and correspondingly obestatin increased during myogen-
esis being sustained throughout terminal differentiation. Auto-
crine action was demonstrated by neutralization of the
endogenous obestatin secreted by differentiating L6E9 cells
using a specific anti-obestatin antibody. Knockdown experi-
ments by preproghrelin siRNA confirmed the contribution of
obestatin to the myogenic program. Furthermore, GPR39
siRNA reduced obestatin action and myogenic differentiation.
Exogenousobestatin stimulationwasalsoshowntoregulatemyo-
blast migration and proliferation. Furthermore, the addition of
obestatin to thedifferentiationmediumincreasedmyogenicdiffer-
entiation of L6E9 cells. The relevance of the actions of obestatin
was confirmed in vivo by the up-regulation of Pax-7,MyoD,Myf5,
Myf6, myogenin, and myosin heavy chain (MHC) in obestatin-in-
fused ratswhen comparedwith saline-infused rats. Thesedata elu-
cidate a novelmechanismwhereby the obestatin/GPR39 system is
coordinately regulated as part of themyogenic program and oper-
ates as an autocrine signal regulating skeletal myogenesis.
The regenerative potential of adult skeletal muscle is mainly
attributed to the heterogeneous population ofmuscle stemcells
known as satellite cells (1, 2). These pluripotent cells, located in
a niche beneath the basal lamina and closely juxtaposed tomus-
cle fiber, are normally mitotically quiescent but can be induced
to enter the cell cycle by weight bearing, trauma, and specific
disease states. Activated satellite cells give rise to a transient
amplifying population of myogenic precursor cells that
undergo several rounds of division before migrating to the site
of damage to enter terminal differentiation (3, 4). Furthermore,
satellite cells also possess the ability to undergo self-renewal to
restock the quiescent satellite cell population (4). At themolec-
ular level, a broad spectrum of signals orchestrates the activa-
tion of satellite cells and repopulation of the quiescent pool.
These signals include the following: basic fibroblast growth fac-
tor (5), hepatocyte growth factor (6), epidermal growth factor
(EGF (7)), insulin-like growth factor-I (IGF-I 5 (8)), myostatin
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(9), Wnt glycoproteins (10, 11), brain-derived neurotrophic
factor (BDNF (12)), calcitonin (13), -chemokine stromal-de-
rived factor 1 (SDF-1 (14)), TNF ligand TWEAK (15), Notch
ligand Delta (16), integrin VLA-4 (17), M-cadherin (18), VEGF
(19), PDGF (20), IL-6 (21), and angiopoietin 1 (22). These sig-
nals determine the intracellular pathways that converge on a
series of transcription and chromatin-remodeling factors to
define the gene and microRNA expression program that
delimitmyogenic identity (2, 4).Myogenic transcription factors
are organized in hierarchical gene expression networks that are
spatiotemporally activated or inhibited during lineage progres-
sion. In particular, the muscle regulatory factor family (MRF),
MyoD, Myf5, myogenin, and MRF4 are essential for myoblast
lineage commitment. TheMRF in conjunction with other tran-
scriptional regulators induces the expression ofmuscle-specific
genes, such as myosin heavy chain (MHC), that determine ter-
minal myogenic differentiation (2, 4, 23).
Regarding the extrinsic regulation of adult myogenesis, the
IGF family and the insulin-like growth factor 1 receptor
(IGF1R) appear to play a key role in regulating skeletal muscle
growth and myogenesis and in maintaining homeostasis in
adult muscle tissues (24). The IGF/IGF1R system stimulates
both myoblast proliferation and myoblast differentiation,
which are twomutually exclusive biological events duringmyo-
genesis. Intriguingly, the IGF/IGF1R system also plays a key
role in adipogenesis (25). This dual activity is determined by the
cell type-specific context in which differential activation of sig-
naling pathways provides an important switching function that
determines the cell fate in the differentiation process (26–28).
Recent works from our laboratory have uncovered that insulin,
through IGF1R, triggers the expression of obestatin during adi-
pocyte differentiation as a key target for preadipocyte commit-
ment to the adipocyte lineage (29, 30). Obestatin, a 23-amino
acid peptide derived from a polypeptide called preproghrelin,
precursor of ghrelin, was originally isolated from the stomach.
It was found to be a circulating peptide whose secretion is pul-
satile with an ultradian rhythmicity similar to the ghrelin and
growth hormone secretion (31). It was reported to be the ligand
for the orphan receptor GPR39, which belongs to the family of
the ghrelin and motilin receptors (32). The autocrine role on
adipogenesis was further supported by the effect of exogenous
obestatin on the expression of master regulators of the adi-
pocyte fate and, consequently, lipid accumulation (30). This
action appears to be related to Akt activation and its down-
stream targets, mammalian target of rapamycin (mTOR) and
S6K1. The relevance of obestatin as a regulator of adipocyte
metabolismwas supported by AS160 phosphorylation, GLUT4
translocation, and increased glucose uptake. In addition to the
adipogenic function, obestatin is amultifunctional peptidewith
roles in pancreatic homeostasis (33) and cancer (34, 35), and it
is associated with the activation of MAPK and Akt signaling
pathways (34, 35). The bidirectional activity of IFG/IGF1R on
adipogenesis and myogenesis, the common mesenchymal pre-
cursor for muscle and fat cells, and the availability of new data
on preproghrelin as the source of key autocrine factors for adi-
pogenesis prompted us to perform further studies on the role of
obestatin as an autocrine/paracrine factor in the regulation of
myogenesis and regeneration following muscle damage. Based
on the cardiotoxin (CTX) injury model, we found that the
obestatin/GPR39 system is up-regulated in damaged muscle.
Using several cellular strategies, we analyzed themitogenic and
myogenic capabilities of this system. Finally, in vivo studies
confirmed the role of obestatin in the regulation of myogenesis
in adult skeletal muscle.
EXPERIMENTAL PROCEDURES
Materials—Rat/mouse obestatin was obtained from Califor-
nia Peptide Research (Napa, CA). Anti-pAkt hydrophobic
motif Ser-473 (HM(Ser-473)), anti-Akt, anti-pERK1/2(Thr-
202/Tyr-204), anti-ERK 1/2, anti-pp38(Tyr-182), anti-p38, and
anti-tubulin antibodies were from Cell Signaling Technology
(Beverly, MA). Anti-GPR39, anti-MHC, anti-p21, and anti-
obestatin (for obestatin neutralization assays) antibodies were
obtained from Abcam (Cambridge, UK). Anti-preproghrelin
antibody was obtained from Phoenix Pharmaceuticals (Burlin-
game, CA). Anti-myogenin, anti-MyoD, anti-Myf5, anti-Pax-7,
anti-Myf6, anti-Six-1, anti-VEGF, anti-VEGF-R2 (flK1), and
anti-PEDF antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA). For immunohistochemistry, anti-
obestatin antibody was from Alpha Diagnostic International
Inc. (SanAntonio, TX). FITC-conjugated goat anti-mouse anti-
body was from Invitrogen. Preproghrelin, GPR39, and control
siRNAs were obtained from Thermo Fisher Scientific (Dhar-
macon). Secondary antibodies and enhanced chemilumines-
cence detection system were from Thermo Fisher Scientific
(Pierce). ALZET osmotic minipumps (model 1003D) were
purchased from DURECT Corp. (Cupertino, CA). All other
chemical reagents were from Sigma.
Cell Culture andDifferentiation Induction of L6E9Myoblasts—
Rat L6E9 myoblasts were cultured as described by the supplier
(European Collection of Cell Cultures (ECACC), Wiltshire,
UK). L6E9myoblastsweremaintained in growthmedium (GM)
containing DMEM supplemented with 10% fetal bovine serum
(FBS), 100 units/ml penicillin, and 100 units/ml streptomycin.
For routine differentiation, cells were grown to 80% confluence,
and GM was replaced with differentiation medium (DM,
DMEM supplemented with 2% FBS, 100 units/ml penicillin,
and 100 units/ml streptomycin) for 6 days unless otherwise
stated.
Quantitative RT-PCR—For quantitative RT-PCR, total RNA
was isolated with TRIzol (Invitrogen) and DNA-free kit (Invit-
rogen, Applied Biosystems/Ambion) to generate first-strand
cDNA synthesis using a high-capacity cDNA reverse transcrip-
tion kit (Applied Biosystems). Quantitative RT-PCR was per-
formed using an ABI PRISM 7300 HT sequence detection
system (Applied Biosystems). For the analysis of the pre-
proghrelin gene, -actin was used as the housekeeping gene
(TaqMan: Applied Biosystems). The -fold change in gene
expression was calculated using the 2Ct relative quanti-
tation method according to the manufacturer’s guidelines
(Applied Biosystems).
Immunoblot Analysis—Tissue samples or cells were directly
lysed in ice-cold radioimmune precipitation buffer (50 mM
Tris-HCl (pH7.2), 150mMNaCl, 1mMEDTA, 1% (v/v)Nonidet
P-40, 0.25% (w/v) sodium deoxycholate, protease inhibitor
mixture (Sigma), and phosphatase inhibitor mixture (Sigma).
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Lysates were clarified by centrifugation (14,000  g for 15 min
at 4 °C), and the protein concentration was quantified using the
QuantiProTM BCA assay kit (Sigma). For immunoblotting,
equal amounts of protein were fractionated by SDS-PAGE and
transferred onto nitrocellulose membranes. Immunoreactive
bands were detected by enhanced chemiluminescence (Pierce
ECL Western blotting Substrate; Thermo Fisher Scientific,
Pierce).
Immunocytochemistry/Histochemistry—L6E9 cells (myo-
blasts or myotubes) cultured on coverslips were fixed in 96%
ethanol for immunocytochemistry analysis. Muscle samples
were mounted in tissue freezing medium (tragacanth paste)
and snap-frozen in nitrogen-cooled isopentane. Sections, 10
m thick, were mounted on HistoBond adhesion microslides
(Marienfeld, Lauda-Königshofen, Germany). Cells or tissue
samples were consecutively incubated with: 1) primary anti-
body at a dilution of 1:100 in Dako ChemMate antibody diluent
(Dako, Glostrup, Denmark); 2) EnVision peroxidase rabbit
(Dako, Carpentaria, CA) used as the detection system; and
3) 3,3-diaminobenzidine-tetrahydrochloride (Dako liquid
DAB  substrate-chromogen system). Samples were counter-
stainedweakly withHarris’ hematoxylin. Immunohistochemis-
try controls were performed by applying the primary antibody
plus control antigen peptide (10 nmol/ml) to positive samples.
For similar analyses, serial cryostat sections were stained with
hematoxylin/eosin, anti-obestatin, anti-GPR39, anti-MyoD,
and anti-myogenin.
For immunofluorescence analysis, L6E9 cells were cultured
on coverslips and differentiated into myotubes under DM sup-
plemented with obestatin (5 nM) for 6 days. Intact cells were
fixed with 4% buffered paraformaldehyde-PBS for 15 min,
washed, permeabilized, and blocked with PBT (1% Triton
X-100, 1% Tween 20, 5% heat-inactivated normal goat serum,
0.2% BSA in PBS) for 30 min and then incubated with anti-
MHCmouse antibody diluted in PBT (1:400) overnight at 4 °C.
After three washes with PBS, cells were incubated with the sec-
ondary antibody (FITC-conjugate goat anti-mouse antibody) in
PBT (1:1000) for 45 min at 37 °C. DAPI was used to counter-
stain the cell nuclei (Invitrogen). Digital images of cell cultures
were acquired with a Leica TCS-SP2 spectral confocal micro-
scope (Leica Microsystems, Heidelberg, Germany). Five fields
from three independent experiments were randomly taken for
each treatment. The differentiation grade was evaluated based
on the number ofMHC-positive cells above the total number of
nuclei. The number of nuclei within individual myotubes (2
nuclei) was counted for 20–50 myotubes. Myotubes were
grouped into two categories, those with 2–3 nuclei and those
with 4 or more nuclei, and the percentage of myotubes in each
category was calculated relative to untreated cells (36). For
quantification of myofiber cross-section area, cryostat sections
were stained with hematoxylin/eosin, and five randomly cho-
senmicroscopic fields from twodifferent sections in each tissue
block were examined using ImageJ64 analysis software.
Small Interfering RNA (siRNA) Silencing of Gene Expression—
Chemically synthesized double-stranded siRNA duplexes
targeting either preproghrelin or GPR39 were selected from
ON-TARGETplus SMARTpool siRNA from Thermo Fisher
Scientific (Dharmacon; preproghrelin, CCAAGAAGCCACCA-
GCUAA, CUGCUGACUUACAAAUAAA, CAGAGGAGGAG-
CUGGAAAU, and UCAAAGAGGCGCCAGCUAA; GPR39,
ACAAGGGACUCAACUGUAA, UUACGCAGGUAUUGCA-
GAA, CCUGCAAGCUCCACACACGUU, andAGUUUGGCU-
UGUUCAGAUA). An ON-TARGETplus nontargeting siRNA
was used as a control for all siRNA experiments. L6E9 cells were
transfected with Lipofectamine 2000 (Invitrogen).
Invasion/Migration Assay—L6E9 cells were seeded on 6-well
plates, grown to 100% confluence in GM, and then wounded
with a sterile pipette tip to remove cells by linear scratches. The
cells werewashed andmaintained inGMorGM 5 nMobesta-
tin. The progress of migration was photographed immediately
after injury and at 8 and 24 h after wounding, near the crossing
point. The wound was calculated by tracing along the border of
the scratch using the ImageJ64 analysis software and using the
following equation: percentage of wound closure  ((wound
area (0 h)  wound area ( h))/wound area (0 h))  100 (37).
Animals—Adult male Sprague-Dawley rats (250 g; n  20)
were housed in 12-h light/12-h dark cycles with free access to
standard rat chow diet and water. ALZET minipumps (model
1003D) were subcutaneously implanted. The animals were
assigned to one of two matched experimental groups (n 
10/group): 1) 72-hminipump subcutaneously implanted group
(containing obestatin (300 nmol/kg body weight/24 h)); and 2)
72-h minipump subcutaneous control group (containing
saline). These minipumps hold 100 l of volume and deliver 1
l/h. After 72 h, rats were sacrificed, and the soleus and gastro-
cnemius muscle tissues were snap-frozen in liquid nitrogen for
Western blot analysis. All experimental procedures were
approved by the Animal Care Committee at the Universidad de
Santiago de Compostela in accordance with European Union
normative for the use of experimental animals.
Muscle Injury Model—Gastrocnemius muscles from rats
were impaired, along their entire length, with four intramuscu-
lar injections per muscle with CTX (10 M CTX; 2 l/g body
weight) or equal volume of PBS (38) to ensure equal distribu-
tion throughout the muscle. At different times after injury (6,
24, 48, and 72 h; n  5 per time point), rats were sacrificed, and
gastrocnemiusmuscleswere dissected anddivided for histolog-
ical and Western blot analyses. For histologic analysis, muscle
tissue samples weremounted in tissue freezingmedium (traga-
canth paste) and frozen in isopentane. For Western blot analy-
sis, muscles were snap-frozen in liquid nitrogen. This proce-
dure was approved by the Animal Care Committee at the
Universidad de Santiago de Compostela.
Data Analysis—All values are presented as the means  S.E.
Student t tests were performed to assess the statistical signifi-
cance of two-way analysis. For multiple comparisons, analysis
of variance was employed. p  0.05 was considered as statisti-
cally significant (*).
RESULTS
The Obestatin/GPR39 System Is Expressed in Adult Skeletal
Muscle—As seen in Fig. 1A, the expression of the obestatin/
GPR39 system was detected in adult gastrocnemius skeletal
muscle from male ad libitum rats by immunohistochemistry
(Fig. 1, A.1 and A.4, respectively). No immunostaining was
found when obestatin or GPR39 antibodies were preadsorbed
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with homologous peptides (Fig. 1,A.2 andA.5, respectively). In
contrast, immunostaining was observed when obestatin anti-
body was preadsorbed with ghrelin peptide (Fig. 1A.3). A com-
parative studywith immunoblot analysis demonstratedmoder-
ate obestatin expression in the gastrocnemius when compared
with the stomach (	0.4-fold; Fig. 1A, right panel). In contrast,
higher GPR39 expression in the gastrocnemius than in the
stomach was detected (	1.4-fold).
Obestatin/GPR39 System Is Up-regulated in Skeletal Muscle
upon CTX Injury—To examine the obestatin/GPR39 regula-
tion in amodel of skeletal muscle injury and regeneration, CTX
solution (10 M CTX; 2 l/g body weight) (39) or an equal
volume of PBS was injected into the gastrocnemius muscle.
Tissues were analyzed at 6, 24, 48, and 72 h after treatment (n
5 at each time point). As shown in Fig. 1B, immunoblot analysis
revealed that the maximal expression of preproghrelin (	4.5-
fold), obestatin (	1.7-fold), andGPR39 (	2.1-fold) occurred at
24 h after CTX treatment. Maximal protein expression of the
myogenic nuclear factors MyoD (	2.9-fold) and myogenin
(	2.4-fold) paralleled with the expression of preproghrelin,
obestatin, andGPR39 at the 24-h time point (Fig. 1B, left panel).
Immunohistochemical analysis of obestatin, GPR39, MyoD,
FIGURE 1. A, immunohistochemical detection of obestatin (A.1) and GPR39 (A.4) in gastrocnemius muscle (objective magnification 20). Preadsorption
controls were performed, applying the primary antibody plus obestatin (A.2), ghrelin (A.3), or GPR39 control peptide (A.5) (10 nmol/ml per control peptide) to
positive samples. Immunohistochemistry was also performed in the absence of primary antibody (A.6). Right panel, immunoblot analysis of obestatin and
GPR39 of extracts from stomach and gastrocnemius muscle of control rats (n  5). Results were expressed as a -fold of protein levels in the stomach.
B, preproghrelin, obestatin, and GPR39 expression in the CTX model of gastrocnemius muscle injury. Left panel, relative protein expression of preproghrelin,
obestatin, GPR39, MyoD, and myogenin in CTX- or PBS-injected gastrocnemius muscle was assessed at the indicated time points by immunoblot (n  5 per
group and time point). Protein expression was expressed as a -fold over PBS control muscle. Right panel, representative immunoblot images of gastrocnemius
muscle sections 24 h after PBS or CTX injection. Lower panel, representative images of gastrocnemius muscle sections 24 h after PBS or CTX injection:
hematoxylin/eosin (B1, control, and B2, CTX); immunohistochemical detection of obestatin, GPR39, MyoD, and myogenin after CTX injection (B3, B4, B5, and
B6, respectively; objective magnification 20). C, immunocytochemical detection of obestatin and GPR39 in myoblast and myotube L6E9 cells (objective
magnification 40). D, relative mRNA transcripts of preproghrelin in the course of L6E9 myogenesis. mRNA was quantified by real-time PCR and expressed as
arbitrary units (n  3). E, immunoblot analysis of preproghrelin, obestatin, GPR39, myogenin, and MHC expression in the course of L6E9 myogenesis. Protein
level was expressed as a -fold over control cells in GM (n  3). Immunoblots in A and B are representative of the mean value. Immunoblots in E are representative
of three independent experiments. Data were expressed as the mean  S.E. obtained from intensity scans of independent experiments. *, p  0.05 versus
control values.
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andmyogeninwas also performed at the 24-h time point (Fig. 1,
B.3–B.6). The strongest signal for both obestatin (Fig. 1B.3) and
GPR39 (Fig. 1B.4) occurred in regenerated myofibers (Fig. 1,
B.5 and B.6).
Obestatin Is Up-regulated during Myogenic Differentiation—
To elucidate the role of this system in myogenesis, an in vitro
cell culture model that closely recapitulates the formation and
maintenance of skeletal muscle was utilized: the rat skeletal
muscle L6 myoblasts (subclone E9, L6E9 cells) (40). Upon
reaching confluence, serum was withdrawn to induce the dif-
ferentiation of L6E9 cells from proliferative myoblasts into ter-
minally differentiated myotubes to permit fusion and form
multinucleated cells that expressmarkers of differentiated skel-
etal muscle. As shown in Fig. 1C, L6E9 myotubes, obtained
during a 6-day differentiation period, showed a stronger
obestatin expression when compared with that observed in
L6E9 myoblast cells (Fig. 1C.3 when compared with Fig. 1C.1).
In contrast, GPR39 was detected in L6E9 in both myoblast and
myotube cells (Fig. 1, C.2 and C.4, respectively). These results
led us to focus on preproghrelin expression during myogenesis
as a source of obestatin. Preproghrelin expression was exam-
ined at the mRNA and protein levels by real-time PCR and
immunoblot, respectively, from samples taken at the prolifera-
tive state and throughout differentiation. Within 6 h of differ-
entiation, the preproghrelin mRNA levels experienced a rapid
increase (	1.6-fold; Fig. 1D), which subsequently returned to
basal level values by 48 h of induction. Transcript expression
increased again from 72 h, reaching maximal levels at 144 h
after induction of differentiation (	2.3-fold). As shown in Fig.
1E, immunoblot analysis confirmed the dynamic regulation of
preproghrelin expression at the time of differentiation into
myotubes, with a rapid increase at the 6-h time point, reaching
a maximum at 24 h after induction of differentiation (	4.4-
fold) concomitantwith the rise of preproghrelinmRNAexpres-
sion. Intriguingly, preproghrelin protein expression began to
decrease 48 h after induction of differentiation (	2.1-fold at
144 h), remaining at sustained but reduced levels during termi-
nal differentiation; however, the levels remained higher than in
myoblast cells (Fig. 1E). Obestatin peptide expression closely
paralleled the expression of preproghrelin (	4.5- and 3.0-fold
at 24 and 144 h, respectively). GPR39 protein expression
showed maximal expression levels at two time points: 6 and
144h (	2.9- and 2.6-fold, respectively), concomitantwithmax-
imum expression levels of the myogenic transcription factor
myogenin (Fig. 1E). The expression of MHC reached maximal
levels 72 h after induction, which marked the progression of
terminal differentiation (Fig. 1E).
Autocrine/Paracrine Role of Obestatin on Myogenesis—The
effect of acute obestatin deficiency was first determined by pre-
proghrelin knockdown bymeans of siRNAprior to induction of
myogenic differentiation. Under these conditions, the con-
structs decreased preproghrelin level by 57  2% relative to
siRNAcontrol (si-control; Fig. 2A) during a 96 h-differentiation
period. Silencing of preproghrelin (si-preproghrelin) decreased
myogenin andMHCexpression levelswith respect to si-control
(46  6 and 33  7%, respectively; Fig. 2A). Correspondingly,
the cell cycle arrest protein p21 expressionwas decreased in the
presence of si-preproghrelin (26  2%; Fig. 2A). The individual
autocrine role of obestatin was tested using a neutralizing
obestatin antibody (Ab) (30). L6E9 cells were maintained in
GM, DM, anti-obestatin Ab (5 g/l) in DM, obestatin  anti-
obestatin Ab (1:1, w/w) in DM, or preimmune IgG (5 g/l) in
DM during a 6-day differentiation period in which DM plus
reactive were replaced every 24 h. As shown in Fig. 2B, anti-
obestatin Ab reduced myogenin and MHC expression levels
with respect to standard differentiation conditions (40  3 and
89  2%, respectively), whereas obestatin  anti-obestatin Ab
or preimmune IgG treatments, used as Ab controls, did not
affect the differentiation marker levels. Simultaneously, Akt
phosphorylation at the C-terminal hydrophobic motif (Ser-
473) (HM(Ser-473); pAkt(Ser-473)) and p38 phosphorylation
at Tyr-182 (pp38(Tyr-183)) showed significant decrease in the
presence of the obestatin neutralizing Ab (60  2 and 30  3%,
respectively; Fig. 2B). Furthermore, the presence of the anti-
obestatin Ab reduced p21 expression (32  1%; Fig. 2B).
GPR39 Regulates Myogenesis—First, the effect of acute
GPR39 deficiency on obestatin signaling was determined by
treatment of L6E9 myoblast cells with siRNA (si-GPR39).
Under these conditions, the constructs decreased GPR39
expression by 69  2% (Fig. 2C). In the presence of si-control,
obestatin-activated Akt(Ser-473) and p38(Tyr-182) phosphor-
ylationwas identical to levels observedwith untransfected cells.
Silencing of GPR39 decreased subsequent pAkt(Ser-473) and
pp38(Tyr-182) with respect to si-control by 61 2 and 52 1%
with treatment of obestatin (5 nM, 10min; Fig. 2C), respectively.
Second, the effect of acute GPR39 deficiency on myogenesis
was further evaluated onmyogenic differentiation. Under these
conditions, the constructs decreased GPR39 expression by
50  3% (Fig. 2D) during a 96-h differentiation period. The
GPR39 knockdown decreased the expression levels of myoge-
nin andMHCby 40 5 and 41 4%with respect to si-control,
respectively (Fig. 2D).
Obestatin Enhances Myogenic Differentiation—To ascertain
the influence of obestatin onmyogenesis, the effect of obestatin
(0.001–100 nM) on intracellular targets leading to either prolif-
eration (ERK1/2) or differentiation (p38 and Akt) was first
assayed in L6E9 myoblasts. pAkt(Ser-473), pp38(Tyr-182), and
pERK1/2(Thr-202/Tyr-204) were observed using different
concentrations of obestatin (0.001–100 nM), and the level of
phosphorylation peaked at 5 nM in L6E9 myoblasts (data not
shown). Fig. 3A shows that myoblast treatment with obestatin
(5 nM) elicited a time-dependent increase in pAkt(Ser-473),
pERK1/2(Thr-202/Tyr-204), and pp38(Tyr-182) protein levels,
which reached a maximum at 10 min. Mitogenic action was
then explored by dose-effect experiments performed on myo-
blasts treated with a range of obestatin concentrations (0.01–
100 nM) in GM (proliferating conditions; Fig. 3B). Maximal
effect in the cell number was observed at 5 nM obestatin (	2.2-
fold). This mitogenic effect was compared with that induced by
ghrelin, under the same range of concentrations (0.01–100 nM)
in GM. As shown in supplemental Fig. 1S, A, ghrelin showed
proliferative capability in L6E9 myoblast cells, although its
effect was lower than that of obestatin for all doses tested.
To assess the activity of obestatin as a promoter of the differ-
entiation process, L6E9 cells were switched to DM supple-
mented with obestatin at a range of concentrations (0.001–100
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nM) for 6 days. As shown in Fig. 3C, the protein levels of myo-
genin andMHC, as detected by immunoblot, were dose-depen-
dent and up-regulated with the maximal effect at 5 nM for both
differentiation markers (	1.7- and 1.6-fold, respectively). The
possibility that obestatin accelerates differentiation was also
investigated (DM  5 nM obestatin for 6 days). Immunoblot
analyses revealed normal kinetics with enhanced protein level
of both myogenin andMHCwhen compared with control cells
(DM for 6 days; supplemental Fig. 1S, B). These results were
confirmed by quantifying the differentiation grade by immuno-
fluorescence. After 6 days, obestatin-treated cells (DM  5 nM
obestatin) increased by	250% inmyotube number when com-
pared with control cells (DM; Fig. 3D). Moreover, myotubes
were grouped into two categories, those with 2–3 nuclei and
those with 4 or more nuclei (36). As shown in Fig. 3E, 	22% of
control myotubes contained 4 nuclei, versus 	67% of obesta-
tin-treated cells (DM  5 nM obestatin). This effect represents
an increase of	3.4-fold respect to control cells (DM). Next, we
performed invasion/migration assays on L6E9 myoblast cells
supplemented with obestatin (5 nM). Confluent monolayers of
cells were physically wounded with a scratch and allowed to
migrate to heal for 8 and 24 h, eliminating the possibility of
proliferation accounting for the wound closure. As shown in
Fig. 3D, at 8 h after initial scratch, obestatin-treated cells exhib-
FIGURE 2. A, effect of siRNA depletion of preproghrelin on myogenesis. L6E9 cells were transfected with preproghrelin siRNA prior to induction of myogenesis
for 96 h. Expression of myogenin, MHC, p21, and preproghrelin was denoted as a -fold of the respective levels in control siRNA-transfected cells (n  3). B,
autocrine role of obestatin on myogenesis. Differentiating L6E9 cells were maintained in DM, DM supplemented with anti-obestatin antibody (5 g/l;
anti-obestatin Ab), obestatin  anti-obestatin Ab (1:1, w/w), or preimmune IgG (5 g/l) for 6 days. Expression of pp38(Tyr-182), pAkt(Ser-473), or p21 is
expressed as a -fold of respective expressions in DM control (n  6). C, effect of GPR39 knockdown by siRNA on obestatin-activated pAkt(Ser-473) and
pp38(Tyr-182) in L6E9 myoblast cells (5 nM, 5 min). GPR39 was expressed as a -fold of its level to control siRNA-transfected cells (n  3). Activation of Akt and
p38 was expressed relative to control siRNA-transfected cells. D, effect of siRNA depletion of GPR39 on myogenesis. L6E9 cells were transfected with GPR39
siRNA prior to induction of myogenesis for 96 h. Expression of myogenin and MHC was expressed as a -fold of the respective levels to control siRNA-transfected
cells (n  3). Immunoblots in A, B, C, and D are representative of three independent experiments. Data were expressed as the mean  S.E. obtained from
intensity scans of independent experiments. *, p  0.05 versus control values.
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ited an 	53% increase in the invasion/migration capability
when compared with the control. At 24 h after scratch, the
increase was 	21% for obestatin-treated cells when compared
with control.
To confirm the observation that obestatin activates the dif-
ferentiation program, the ability of this peptide to activate the
differentiation program under GM (GM  5 nM obestatin) was
evaluated in L6E9myoblast cells for 6 days. The protein levels of
myogenin and MHC, as detected by immunoblot, were signifi-
cantly increased when compared with control cells in GM
(	4.2- and 14-fold, respectively; supplemental Fig. 1S, C). The
expression for both differentiationmarkerswas induced to sim-
ilar levels upon 6 days of treatment with ghrelin (5 nM; supple-
mental Fig. 1S, C).
Obestatin Regulates Myogenic Markers in Vivo—Based on
the short half-life of this peptide (	22 min), osmotic mini-
pumps were selected for in vivo obestatin administration (41).
Male rats received a 72-h continuous subcutaneous infusion of
obestatin (300 nmol/kg of bodyweight/24 h) (30), and dissected
gastrocnemius and soleus tissues were processed for immuno-
blot analysis. Levels of Pax-7, Myf5, MyoD, myogenin, Myf6,
andMHCwere up-regulated in gastrocnemius and soleusmus-
cle tissues from obestatin-treated rats when compared with
control tissues (Fig. 4A). After 72 h of infusion, a significant
FIGURE 3. A, time course of the effect of obestatin (5 nM) in L6E9 myoblast cells on pAkt(Ser-473), pERK1/2(Thr-202/Tyr-204), pAMPK(Thr-172), and pp38(Tyr-
182) (n  3). AMPK, AMP-activated protein kinase. B, dose-response effect of obestatin (0.01–100 nM) on L6E9 myoblast cell proliferation (48 h, n  5). Co: cells
initially seeded. Control: cells maintained 48 h in GM. C, dose-response effect of obestatin (0.01–100 nM) on differentiating L6E9 cells for 6 days (n  6). Levels
of myogenin and MHC were represented as a -fold of respective expression in GM. D, left panel, immunofluorescence detection of MHC and DAPI (objective
magnification 20) in L6E9 myotube cells under DM (control) or DM  obestatin (5 nM) at the 6-day point after stimulation. Right panel, the differentiation
grade was evaluated based on the number of MHC-positive cells above total nuclei and expressed as a -fold of control. E, representative images used to
determined the number of nuclei within individual myotubes (at least two nuclei) in L6E9 myotube cells under DM (control) or DM  obestatin (5 nM) at the
6-day point after stimulation (left panel, objective magnification 20). Myotubes were grouped into two categories, and the percentage of myotubes in each
category was determined (right panel). F, left panel, L6E9 myoblast cells at 100% confluence were wounded with a sterile pipette tip to remove cells. Photo-
graphs were taken (objective magnification 10) at 0, 8, and 24 h after injury. Right panel, wound closure was evaluated using the equation described under
“Experimental Procedures.” Immunoblots in A and C are representative of three and six independent experiments, respectively. For these panels, data were
expressed as the mean  S.E. obtained from intensity scans of independent experiments. For panels D and E, data were expressed as the mean  S.E. as
described under “Experimental Procedures.” *, p  0.05 versus control values.
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increase in myofiber diameters was observed in gastrocnemius
muscle (Fig. 4A, right panel). Aminor effect was observed in the
soleus myofiber area (Fig. 4A, right panel). Moreover, obestatin
treatment resulted in a significant up-regulation of the VEGF
and VEGF-R2 expression in both gastrocnemius and soleus
muscle when compared with controls (Fig. 4B). Conversely, the
PEDF expression level was significantly down-regulated in gas-
trocnemius and soleus muscle under obestatin treatment (Fig.
4B).
DISCUSSION
In the present study, we have shown that healthy skeletal
muscle expresses obestatin and GPR39, and this expression
strikingly increased upon muscle injury. In vitro, obestatin was
preferentially expressed by L6E9 myotubes, whereas GPR39
was equally expressed in both myoblast and myotube cells.
Expression of both obestatin and GPR39 was coordinately up-
regulated during the early stages ofmyogenesis, and their levels
remained sustained throughout terminal differentiation of
L6E9 cells. Functionally, blocking obestatin during myogenesis
induced a decrease in myogenic-associated markers (myoge-
nin, MHC). Silencing of preproghrelin or GPR39 expression
produced similar results. Obestatin stimulation of undifferen-
tiated L6E9 cells promoted mitogenic activity and migration
function of myoblasts. Furthermore, this peptide promoted
myogenic differentiation, increasing the expression of myo-
genic markers, without changes to the kinetics of differentia-
tion. Additionally, these results were supported by in vivo test-
ing of the gastrocnemius and soleusmuscle obtained frommale
rats under continuous subcutaneous infusion of obestatin. The
testing of this peptide showed an up-regulation of a set of tran-
scription factors regulating myogenesis: (i) markers associated
with satellite cell activation: Pax-7 andMyf5; (ii) markers asso-
ciated with early differentiation: MyoD, myogenin, and Myf6;
FIGURE 4. Effect of 72-h continuous subcutaneous infusion of obestatin (300 nmol/kg of body weight/24 h; n  10) on myogenic markers (MyoD, Myf5,
Pax-7, myogenin, Myf6, and MHC) and myofiber cross-section area (A) and VEGF, VEGFR2, and PEDF expression (B). Protein levels were expressed as a
-fold of control obtained from a 72-h minipump subcutaneously implanted in saline group (n  10 per group). Immunoblots in A and B are representative of
mean values from each rat group. In A, hematoxylin/eosin-stained gastrocnemius (right, upper panel) and soleus (right, lower panel) sections are representative
of the mean value of total cross-section area. Data were expressed as the mean  S.E. *, p  0.05 versus control values.
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and (iii) a marker associated with late differentiation: MHC.
Altogether, these observations demonstrated that the obesta-
tin/GPR39 system is involved in myogenesis and that obestatin
is expressed by differentiatingmyogenic precursors to function
in an autocrine manner.
After injury, satellite cells are activated and enter the cell
cycle to proliferate, and eventually, they fuse to replace degen-
eratedmuscle fibers, preservingmuscle structure and function.
Several signals, derived both from damaged fibers and from
infiltrating cells, are involved in satellite cell activation (1, 42).
From the data presented thus far, obestatin should be incorpo-
rated into the list of myogenic regulatory factors derived from
damaged fibers. Based on its overexpression in muscle injury,
its up-regulation during myogenesis, and its promoter role on
myogenic differentiation and fusion of L6E9 cells, it is possible
to speculate that obestatin exerts an autocrine effect on the
skeletal myogenic process. The fact that preproghrelin ex-
pression increased in the course of differentiation and
remained sustained throughout terminal differentiation of
L6E9 cells supports this hypothesis. Furthermore, preproghre-
lin knockdown experiments uncovered its contribution to
myogenesis, although it would implicate both ghrelin and
obestatin. The myogenic role of obestatin is supported by neu-
tralization of this peptide with a specific antibody in L6E9 cells,
which reduced its myogenic potential through myogenin and
MHCdown-regulation. Further support for amyogenic role for
obestatin is demonstrated by the effect on the activation and
proliferation of myoblasts, with the resulting growth arrest by
contact and initiation ofmyogenesis, e.g.myogenesis activation
of proliferating myoblasts in GM. The increased expression of
myogenic regulator factors, Pax-7, Myf5, MyoD, myogenin,
Myf6, andMHC (23), associated with subcutaneous infusion of
obestatin in rats reinforces this suggestion. Considering the
myogenic characteristics of ghrelin and des-acyl ghrelin previ-
ously described (44), we hypothesized that preproghrelin-de-
rived peptides mutually contribute to myogenesis as pro-myo-
genic factors, as corroborated by the mitogenic and myogenic
roles for ghrelin and obestatin described in the present work.
Although the myogenic characteristics of ghrelin found in this
study are in agreement with previous works (44), the mitogenic
action of ghrelin appears to be in contradiction with a previous
study showing inhibition of C2C12 myoblast cells (44). Even if
the role of ghrelin and des-acyl ghrelin in mitogenesis remains
unclear and varies depending on the nature of the study, the
myogenic properties of preproghrelin-derived peptides rein-
force our hypothesis.
Obestatin hasmultiple functional properties, and its capacity
to stimulate myoblast proliferation, migration, and differentia-
tion in vitro is particularly interesting. In L6E9 myoblasts,
obestatin was shown to enhance ERK, Akt, and p38 activities.
These pathways are activated by regeneration signals and dem-
onstrate the ability of muscle progenitors to execute different
stages of the regeneration program: (a) the ERK/MAP pathway
activates cell proliferation and migration (45, 46); (b) the Akt
pathway promotes cell proliferation, survival, and differentia-
tion (47); and (c) the p38 pathway stimulates cell cycle arrest
and terminal differentiation (48). The convergence of these
pathways at the chromatin level defines the mechanism for
integration of mitogenic and myogenic signals to direct the
transition from quiescence to terminal differentiation (49).
Thus, the range of obestatin functions, together with its expres-
sion in normal and regenerating skeletal muscle, is consistent
with a role in regulating myofiber formation and regeneration.
In this regard, obestatin shows functional similarity with the
insulin-like growth factors (IGF-I and IGF-II) because both fac-
tors have the capacity to promote both proliferation and differ-
entiation of muscle cells (45, 50).
Silencing of GPR39 expression in L6E9 myoblast cells dem-
onstrated that this G protein-coupled receptor is the extracel-
lular target for obestatin action. Although there is ongoing con-
troversy regarding GPR39 (51, 52), our findings are consistent
with the role of this receptor on obestatin signaling in preadi-
pocyte 3T3-L1 cells (29, 30) and in gastrointestinal and adipose
tissues (32). The expression of GPR39 in L6E9 cells and its
changes during myogenesis further suggest a role for GPR39 in
this process. Definitive evidence for the requirement of GPR39
in myogenesis came from the observation that its knockdown
by siRNA significantly diminished the myogenic capacity of
L6E9 cells. Furthermore, the preproghrelin expression up-reg-
ulation and, as a consequence, the increase of obestatin biosyn-
thesis and secretion bymyotubes, togetherwith its faint expres-
sion in myoblasts, lead us to speculate that obestatin might
exert a paracrine role on myoblasts via a GPR39-dependent
mechanism. Similarly, the obestatin/GPR39 system exerts an
autocrine/paracrine control on adipogenesis (30). Combined,
these all point to the role of obestatin/GPR39 signaling as a key
component for proper skeletal and adipose tissue development.
In fact, our recent results underscored a key role for pre-
proghrelin-derived peptides on adipogenesis through an auto-
crine/paracrine mechanism (29).
Male rats under continuous subcutaneous infusion of
obestatin showed amodified expression of transcription factors
that regulate the progression through the myogenic lineage in
soleus and gastrocnemius muscle tissue. Up-regulation of
Pax-7 expression might be indicative of a control on satellite
cell activation to enhance myogenic specification and/or to
induce self-renewal (4, 53, 54). It is known that this transcrip-
tion factor ismaintained in satellite cells and proliferatingmyo-
blasts but is down-regulated before differentiation (53–56).
Furthermore, the expression of myogenic regulatory factors is
coordinated by this factor. Indeed, up-regulation of MyoD and
Myf5 was observed in obestatin-treated rats, denoting the con-
version of satellite cells into myoblast (4), although it is not
possible to rule out a role for this peptide in the replenishment
of the satellite cell pool. MyoD and Myf5 are required for the
expression of myogenic precursors and act upstream of Myf6
and myogenin. Accordingly, Myf6 and myogenin were up-reg-
ulated, denoting myoblast differentiation (2). Moreover, MHC
was observed to be up-regulated, as an indication of myogenic
differentiation. Additionally, obestatin was shown to increase
the expression of VEGF and its receptor isoform VEGFR2 in
this tissue. Conversely, PEDF expression was down-regulated.
The expression and role of VEGF as an autocrine myogenic
factor in muscle was previously described (57). Furthermore,
VEGFR2 was shown to be up-regulated during myogenic dif-
ferentiation (57). In addition to its myogenic action, it is
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important to note its known angiogenic role (58). This latter
effect is important in attracting distant vessels to the myo-
blast differentiation sites. This implies that VEGF, produced
by differentiating myocytes, provides the needed vascular-
ization of developing skeletal muscle. This is further sup-
ported by down-regulation of the anti-angiogenic factor
PEDF (43). All together, our data support the view that
obestatin regulates the “hierarchy” of transcription factors
involved in the control of the different stages of the myo-
genic program, including activation, proliferation, and dif-
ferentiation, exerting a role in the expression of VEGF/
VEGFR2 for the potential regulation of the angiogenic
process in skeletal muscle tissue.
In conclusion, we propose that the obestatin/GPR39 system
signaling is involved inmuscle regeneration, in which obestatin
exerts an autocrine function to control the myogenic differen-
tiation program, thereby implicating its potential for use as a
therapeutic agent for the treatment of trauma-induced muscle
injuries or skeletal muscle myopathies.
REFERENCES
1. Chargé, S. B., and Rudnicki, M. A. (2004) Cellular and molecular regula-
tion of muscle regeneration. Physiol. Rev. 84, 209–238
2. Tedesco, F. S., Dellavalle, A., Diaz-Manera, J., Messina, G., and Cossu, G.
(2010) Repairing skeletal muscle: regenerative potential of skeletal muscle
stem cells. J. Clin. Invest. 120, 11–19
3. Kuang, S., Gillespie,M. A., and Rudnicki, M. A. (2008) Niche regulation of
muscle satellite cell self-renewal and differentiation. Cell Stem Cell 2,
22–31
4. Bentzinger, C. F., Wang, Y. X., and Rudnicki, M. A. (2012) Building mus-
cle: molecular regulation of myogenesis Cold Spring Harb. Perspect. Biol.
4, pii: a008342
5. DiMario, J., Buffinger, N., Yamada, S., and Strohman, R. C. (1989) Fibro-
blast growth factor in the extracellular matrix of dystrophic (mdx) mouse
muscle. Science 244, 688–690
6. Tatsumi, R., Anderson, J. E., Nevoret, C. J., Halevy, O., and Allen, R. E.
(1998) HGF/SF is present in normal adult skeletal muscle and is capable of
activating satellite cells. Dev. Biol. 194, 114–128
7. Golding, J. P., Calderbank, E., Partridge, T. A., and Beauchamp, J. R. (2007)
Skeletal muscle stem cells express anti-apoptotic ErbB receptors during
activation from quiescence. Exp. Cell Res. 313, 341–356
8. Machida, S., and Booth, F. W. (2004) Insulin-like growth factor 1 and
muscle growth: implication for satellite cell proliferation. Proc. Nutr. Soc.
63, 337–340
9. McCroskery, S., Thomas, M., Maxwell, L., Sharma, M., and Kambadur, R.
(2003) Myostatin negatively regulates satellite cell activation and self-re-
newal. J. Cell Biol. 162, 1135–1147
10. Brack, A. S., Conboy, M. J., Roy, S., Lee, M., Kuo, C. J., Keller, C., and
Rando, T. A. (2007) Increased Wnt signaling during aging alters muscle
stem cell fate and increases fibrosis. Science 317, 807–810
11. Polesskaya, A., Seale, P., and Rudnicki,M. A. (2003)Wnt signaling induces
the myogenic specification of resident CD45 adult stem cells during
muscle regeneration. Cell 113, 841–852
12. Mousavi, K., and Jasmin, B. J. (2006) BDNF is expressed in skeletal muscle
satellite cells and inhibits myogenic differentiation. J. Neurosci. 26,
5739–5749
13. Fukada, S., Uezumi, A., Ikemoto, M., Masuda, S., Segawa, M., Tanimura,
N., Yamamoto, H., Miyagoe-Suzuki, Y., and Takeda, S. (2007) Molecular
signature of quiescent satellite cells in adult skeletal muscle. StemCells 25,
2448–2459
14. Ratajczak, M. Z., Majka, M., Kucia, M., Drukala, J., Pietrzkowski, Z., Pei-
per, S., and Janowska-Wieczorek, A. (2003) Expression of functional
CXCR4 bymuscle satellite cells and secretion of SDF-1 bymuscle-derived
fibroblasts is associated with the presence of both muscle progenitors in
bone marrow and hematopoietic stem/progenitor cells in muscles. Stem
Cells 21, 363–371
15. Girgenrath, M., Weng, S., Kostek, C. A., Browning, B., Wang, M., Brown,
S. A., Winkles, J. A., Michaelson, J. S., Allaire, N., Schneider, P., Scott,
M. L., Hsu, Y. M., Yagita, H., Flavell, R. A., Miller, J. B., Burkly, L. C., and
Zheng, T. S. (2006) TWEAK, via its receptor Fn14, is a novel regulator of
mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J.
25, 5826–5839
16. Conboy, I. M., Conboy, M. J., Smythe, G. M., and Rando, T. A. (2003)
Notch-mediated restoration of regenerative potential to aged muscl. Sci-
ence 302, 1575–1577
17. Rosen, G. D., Sanes, J. R., LaChance, R., Cunningham, J.M., Roman, J., and
Dean, D. C. (1992) Roles for the integrin VLA-4 and its counter receptor
VCAM-1 in myogenesis. Cell 69, 1107–1119
18. Irintchev, A., Zeschnigk, M., and Starzinski-Powitz A, Wernig, A. (1994)
Expression pattern of M-cadherin in normal, denervated, and regenerat-
ing mouse muscles. Dev. Dyn. 199, 326–337
19. Germani, A., Di Carlo, A.,Mangoni, A., Straino, S., Giacinti, C., Turrini, P.,
Biglioli, P., and Capogrossi, M. C. (2003) Vascular endothelial growth
factor modulates skeletal myoblast function. Am. J. Pathol. 163,
1417–1428
20. Sejersen, T., Betsholtz, C., Sjölund,M., Heldin, C. H.,Westermark, B., and
Thyberg, J. (1986) Rat skeletal myoblasts and arterial smooth muscle cells
express the gene for the A chain but not the gene for the B chain (c-sis) of
platelet-derived growth factor (PDGF) and produce a PDGF-like protein.
Proc. Natl. Acad. Sci. U.S.A. 83, 6844–6848
21. Cantini, M., Massimino, M. L., Rapizzi, E., Rossini, K., Catani, C., Dalla
Libera, L., andCarraro, U. (1995)Human satellite cell proliferation in vitro
is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s)
released by activated monocytes. Biochem. Biophys. Res. Commun. 216,
49–53
22. Abou-Khalil, R., Le Grand, F., Pallafacchina, G., Valable, S., Authier, F. J.,
Rudnicki, M. A., Gherardi, R. K., Germain, S., Chretien, F., Sotiropoulos,
A., Lafuste, P.,Montarras, D., and Chazaud, B. (2009) Autocrine and para-
crine angiopoietin 1/Tie-2 signaling promotes muscle satellite cell self-
renewal. Cell Stem Cell 5, 298–309
23. Braun, T., and Gautel, M. (2011) Transcriptional mechanisms regulating
skeletal muscle differentiation, growth, and homeostasis. Nat. Rev. Mol.
Cell Biol. 12, 349–361
24. Clemmons, D. R. (2009) Role of IGF-I in skeletal muscle mass mainte-
nance. Trends Endocrinol. Metab. 20, 349–356
25. Rosen, E. D., and MacDougald, O. A. (2006) Adipocyte differentiation
from the inside out. Nat. Rev. Mol. Cell Biol. 7, 885–896
26. Sordella, R., Jiang, W., Chen, G. C., Curto, M., and Settleman, J. (2003)
Modulation of Rho GTPase signaling regulates a switch between adipo-
genesis and myogenesis. Cell 113, 147–158
27. Shefer, G., Wleklinski-Lee, M., and Yablonka-Reuveni, Z. (2004) Skeletal
muscle satellite cells can spontaneously enter an alternativemesenchymal
pathway. J. Cell Sci. 117, 5393–5404
28. Park, K.W., Halperin, D. S., and Tontonoz, P. (2008) Before they were fat:
adipocyte progenitors. Cell Metab. 8, 454–457
29. Gurriarán-Rodríguez, U., Al-Massadi, O., Crujeiras, A. B., Mosteiro, C. S.,
Amil-Diz, M., Beiroa, D., Nogueiras, R., Seoane, L. M., Gallego, R., Pazos,
Y., Casanueva, F. F., and Camiña, J. P. (2011) Preproghrelin expression is a
key target for insulin action on adipogenesis. J. Endocrinol. 210, R1–7
30. Gurriarán-Rodríguez, U., Al-Massadi, O., Roca-Rivada, A., Crujeiras,
A. B., Gallego, R., Pardo,M., Seoane, L.M., Pazos, Y., Casanueva, F. F., and
Camiña, J. P. (2011) Obestatin as a regulator of adipocyte metabolism and
adipogenesis. J. Cell Mol. Med. 15, 1927–1940
31. Zhang, J. V., Ren, P. G., Avsian-Kretchmer, O., Luo, C. W., Rauch, R.,
Klein, C., and Hsueh, A. J. (2005) Obestatin, a peptide encoded by the
ghrelin gene, opposes ghrelin’s effects on food intake. Science 310,
996–999
32. Zhang, J. V., Jahr, H., Luo, C. W., Klein, C., Van Kolen, K., Ver Donck, L.,
De, A., Baart, E., Li, J., Moechars, D., and Hsueh, A. J. (2008) Obestatin
induction of early-response gene expression in gastrointestinal and adi-
pose tissues and the mediatory role of G protein-coupled receptor,
GPR39.Mol. Endocrinol. 22, 1464–1475
Obestatin/GPR39 and Myogenesis
38388 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 45 • NOVEMBER 2, 2012
33. Granata, R., Settanni, F., Gallo, D., Trovato, L., Biancone, L., Cantaluppi,
V., Nano, R., Annunziata,M., Campiglia, P., Arnoletti, E., Ghè, C., Volante,
M., Papotti, M., Muccioli, G., and Ghigo, E. (2008) Obestatin promotes
survival of pancreatic -cells and human islets and induces expression of
genes involved in the regulation of -cell mass and function. Diabetes 57,
967–979
34. Pazos, Y., Alvarez, C. J., Camiña, J. P., and Casanueva, F. F. (2007) Stimu-
lation of extracellular signal-regulated kinases and proliferation in the
human gastric cancer cells KATO-III by obestatin. Growth Factors 25,
373–381
35. Alvarez, C. J., Lodeiro,M., Theodoropoulou,M., Camiña, J. P., Casanueva,
F. F., and Pazos, Y. (2009) Obestatin stimulates Akt signalling in gastric
cancer cells through -arrestin-mediated epidermal growth factor recep-
tor transactivation. Endocr. Relat. Cancer 16, 599–611
36. Horsley, V., Friday, B. B., Matteson, S., Kegley, K. M., Gephart, J., and
Pavlath, G. K. (2001) Regulation of the growth of multinucleated muscle
cells by an NFATC2-dependent pathway. J. Cell Biol. 153, 329–338
37. Goetsch, K. P., and Niesler, C. U. (2011) Optimization of the scratch assay
for in vitro skeletal muscle wound healing analysis. Anal. Biochem. 411,
158–160
38. Toschi, A., Severi, A., Coletti, D., Catizone, A., Musarò, A., Molinaro, M.,
Nervi, C., Adamo, S., and Scicchitano, B.M. (2011) Skeletal muscle regen-
eration in mice is stimulated by local overexpression of V1a-vasopressin
receptor.Mol. Endocrinol. 25, 1661–1673
39. Zeng, L., Akasaki, Y., Sato, K., Ouchi, N., Izumiya, Y., andWalsh, K. (2010)
Insulin-like 6 is induced by muscle injury and functions as a regenerative
factor. J. Biol. Chem. 285, 36060–36069
40. Nadal-Ginard, B. (1978) Commitment, fusion, and biochemical differen-
tiation of a myogenic cell line in the absence of DNA synthesis. Cell 15,
855–864
41. Zizzari, P., Longchamps, R., Epelbaum, J., and Bluet-Pajot, M. T. (2007)
Obestatin partially affects ghrelin stimulation of food intake and growth
hormone secretion in rodents. Endocrinology 148, 1648–1653
42. Ten Broek, R. W., Grefte, S., and Von den Hoff, J. W. (2010) Regulatory
factors and cell populations involved in skeletal muscle regeneration.
J. Cell. Physiol. 224, 7–16
43. Ek, E. T., Dass, C. R., and Choong, P. F. (2006) PEDF: a potential molecular
therapeutic target with multiple anti-cancer activities. Trends Mol. Med.
12, 497–502
44. Filigheddu, N., Gnocchi, V. F., Coscia, M., Cappelli, M., Porporato, P. E.,
Taulli, R., Traini, S., Baldanzi, G., Chianale, F., Cutrupi, S., Arnoletti, E.,
Ghè, C., Fubini, A., Surico, N., Sinigaglia, F., Ponzetto, C., Muccioli, G.,
Crepaldi, T., andGraziani, A. (2007)Ghrelin and des-acyl ghrelin promote
differentiation and fusion of C2C12 skeletal muscle cells. Mol. Biol. Cell
18, 986–994
45. Mourkioti, F., and Rosenthal, N. (2005) IGF-1, inflammation, and stem
cells: interactions during muscle regeneration. Trends Immunol. 26,
535–542
46. Leloup, L., Daury, L., Mazères, G., Cottin, P., and Brustis, J. J. (2007) In-
volvement of the ERK/MAP kinase signalling pathway in milli-calpain
activation and myogenic cell migration. Int. J. Biochem. Cell Biol. 39,
1177–1189
47. Wu, M., Falasca, M., and Blough, E. R. (2011) Akt/protein kinase B in
skeletal muscle physiology and pathology. J. Cell Physiol. 226, 29–36
48. Lluís, F., Perdiguero, E., Nebreda, A. R., and Muñoz-Cánoves, P. (2006)
Regulation of skeletalmuscle gene expression by p38MAPkinases.Trends
Cell Biol. 16, 36–44
49. Serra, C., Palacios, D., Mozzetta, C., Forcales, S. V., Morantte, I., Ripani,
M., Jones, D. R., Du, K., Jhala, U. S., Simone, C., and Puri, P. L. (2007)
Functional interdependence at the chromatin level between the MKK6/
p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol.
Cell 28, 200–213
50. Matheny, R. W., Jr., Nindl, B. C., and Adamo, M. L. (2010) Minireview:
Mechano-growth factor: a putative product of IGF-I gene expression in-
volved in tissue repair and regeneration. Endocrinology 151, 865–875
51. Chartrel, N., Alvear-Perez, R., Leprince, J., Iturrioz, X., Reaux-Le Goazigo,
A., Audinot, V., Chomarat, P., Coge, F., Nosjean, O., Rodriguez, M., Gal-
izzi, J. P., Boutin, J. A., Vaudry, H., and Llorens-Cortes, C. (2007) Com-
ment on “Obestatin, a peptide encoded by the ghrelin gene, opposes ghre-
lin’s effects on food intake”. Science 315, 766
52. Holst, B., Egerod, K. L., Schild, E., Vickers, S. P., Cheetham, S., Gerlach,
L. O., Storjohann, L., Stidsen, C. E., Jones, R., Beck-Sickinger, A. G., and
Schwartz, T.W. (2007) GPR39 signaling is stimulated by zinc ions but not
by obestatin. Endocrinology 148, 13–20
53. Wang, Y. X., and Rudnicki, M. A. (2012) Satellite cells, the engines of
muscle repair. Nat. Rev. Mol. Cell Biol. 13, 127–133
54. Olguin, H. C., and Olwin, B. B. (2004) Pax-7 up-regulation inhibits myo-
genesis and cell cycle progression in satellite cells: a potential mechanism
for self-renewal. Dev. Biol. 275, 375–388
55. Hu, P., Geles, K. G., Paik, J. H., DePinho, R. A., and Tjian, R. (2008) Code-
pendent activators directmyoblast-specificMyoD transcription.Dev. Cell
15, 534–546
56. McKinnell, I. W., Ishibashi, J., Le Grand, F., Punch, V. G., Addicks, G. C.,
Greenblatt, J. F., Dilworth, F. J., and Rudnicki, M. A. (2008) Pax7 activates
myogenic genes by recruitment of a histone methyltransferase complex.
Nat. Cell Biol. 10, 77–84
57. Bryan, B. A., Walshe, T. E., Mitchell, D. C., Havumaki, J. S., Saint-Geniez,
M., Maharaj, A. S., Maldonado, A. E., and D’Amore, P. A. (2008) Coordi-
nated vascular endothelial growth factor expression and signaling during
skeletal myogenic differentiation.Mol. Biol. Cell 19, 994–1006
58. Patel-Hett, S., and D’Amore, P. A. (2011) Signal transduction in vasculo-
genesis and developmental angiogenesis. Int. J. Dev. Biol. 55, 353–363
Obestatin/GPR39 and Myogenesis
NOVEMBER 2, 2012 • VOLUME 287 • NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 38389
